group of investigators has uniquely contributed to defining the optimal treatment strategy in patients with ISR. The RIBS V trial demonstrated superior angiographic performance of DES over DEB at 6 to 9 months (5). The present study shows that at 3-year follow-up, there was also a significantly lower rate of target lesion revascularization in the DES arm (2% vs. 8%; p ¼ 0.04). It is notable that the need for target lesion revascularization beyond 1 year was similar in both groups (1% vs. 2.1%; p ¼ 0.54), meaning that the overall rate was driven mainly by events within the first year after intervention.
The present data add valuable information to the existing evidence on the relative merits of DEB and DES for treatment of both BMS and DES ISR. Table 1 Heart Alliance, Munich, Germany. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. 
